Global pharmaceutical giant Pfizer Inc. announced that the company’s trial on a potential treatment for alopecia areata achieved the study’s primary efficacy endpoint.

The U.S. Food and Drug Administration granted Eli Lilly and Company and Incyte Corporation Breakthrough Therapy designation for baricitinib for alopecia areata (AA).

Pharma companies from across the globe provide updates on their pipelines and business.